doi:10.3969/j.issn.1004-583X.2022.01.017

Abstract

CLC Number:

R743.3

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.01.017

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I1/87

References 33

[1]	王陇德, 刘建民, 杨弋, 等. 我国脑卒中防治仍面临巨大挑战——《中国脑卒中防治报告2018》概要[J]. 中国循环杂志, 2019, 34(2):105-119.
[2]	Seners P, Turc G, Oppenheim C, et al. Incidence, causes and predictors of neurological deterioration occurring within 24h following acute ischaemic stroke: A systematic review with pathophysiological implications[J]. J Neurol Neurosurg Psychiatry, 2015, 86(1):87-94. doi: 10.1136/jnnp-2014-308327 URL
[3]	Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2018, 39(2):119-177. doi: 10.1093/eurheartj/ehx393 pmid: 28886621
[4]	国家卫生计生委合理用药专家委员会, 中国药师协会. 急性ST段抬高型心肌梗死溶栓治疗的合理用药指南(第2版)[J]. 中国医学前沿杂志(电子版), 2019, 11(1):40-65.
[5]	王炜, 杨华, 苏晞, 等. 替罗非班联合PCI对老年急性心肌梗死患者心功能及左室重构的影响[J]. 疑难病杂志, 2018, 17(12):1311-1315.
[6]	Yang M, Huo X, Miao Z, et al. Platelet glycoprotein Ⅱb/Ⅲa receptor inhibitor tirofiban in acute ischemic stroke[J]. Drugs, 2019, 79(5):515-529.
[7]	吕功伟, 李国忠. 进展性缺血性卒中研究进展[J]. 中华实用诊断与治疗杂志, 2016, 30(6):534-536.
[8]	解红, 刘学政, 刘新桥. 进展性缺血性脑卒中的发病机制和危险因素研究进展[J]. 中西医结合心脑血管病杂志, 2016, 14(6):612-614.
[9]	Seners P, Baron JC. Revisiting 'progressive stroke': Incidence, predictors, pathophysiology, and management of unexplained early neurological deterioration following acute ischemic stroke[J]. J Neurol, 2018, 265(1):216-225. doi: 10.1007/s00415-017-8490-3 URL
[10]	Birschel P, Ellul J, Barer D. Progressing stroke: Towards an internationally agreed definition[J]. Cerebrovasc Dis, 2004, 17(2-3):242-252. pmid: 14718754
[11]	彭斌, 吴波. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9):666-682.
[12]	Kim JT, Heo SH, Yoon W, et al. Clinical outcomes of patients with acute minor stroke receiving rescue IA therapy following early neurological deterioration[J]. J Neurointerv Surg, 2016, 8(5):461-465. doi: 10.1136/neurintsurg-2015-011690 URL
[13]	中国卒中学会, 中国卒中学会神经介入分会, 中华预防医学会卒中预防与控制专业委员会介入学组. 替罗非班在动脉粥样硬化性脑血管疾病中的临床应用专家共识[J]. 中国卒中杂志, 2019, 14(10):1034-1044.
[14]	贺国华, 王振, 易海波. 替罗非班注射液治疗急性进展性脑梗死的临床疗效及安全性分析[J]. 中国实用神经疾病杂志, 2019, 22(17):1885-1891.
[15]	Gong J, Shang J, Yu H, et al. Tirofiban for acute ischemic stroke: Systematic review and meta-analysis[J]. Eur J Clin Pharmacol, 76(4):475-481. doi: 10.1007/s00228-019-02817-8 URL
[16]	尹其舵, 李正侠, 耿万杰, 等. 替罗非班在急性进展性脑梗死中应用[J]. 现代医学, 2020, 48(8):966-970.
[17]	王升, 刘梦, 郑远征, 等. 小剂量替罗非班与双抗治疗进展性脑卒中的疗效对比及安全性评价[J]. 中国实用神经疾病杂志, 2017, 20(8):23-25.
[18]	姜文洲. 替罗非班应用于急性进展性脑梗死的临床疗效及安全性研究[J]. 中国临床医生杂志, 2020, 48(12):53-55.
[19]	Philipps J, Thomalla G, Glahn J, et al. Treatment of progressive stroke with tirofiban--experience in 35 patients[J]. Cerebrovasc Dis, 2009, 28(5):435-438. doi: 10.1159/000235987 pmid: 19738371
[20]	刘书芳. 替罗非班治疗急性进展性脑梗死效果及对炎症水平影响[J]. 临床研究, 2020, 28(11):57-58.
[21]	罗晓晨, 刘永江, 王荣英. 替罗非班对急性进展性脑梗死患者基质金属蛋白酶水平的影响[J]. 中国临床医生杂志, 2020, 48(6):54-57.
[22]	刘银芳, 曹心慧, 张晓曼. 注射用丹参多酚酸联合替罗非班对急性进展性脑梗死患者NIHSS评分和mRS评分的影响[J]. 药物评价研究, 2020, 43(8):1635-1638+1650.
[23]	侯琳琳. 急性进展性脑梗死患者应用替罗非班的临床疗效和安全性观察[J]. 中国现代医生, 2021, 59(13):46-49.
[24]	崔凡凡. 不同抗血小板药物方案治疗进展性脑卒中的临床疗效评价[D]. 唐山:华北理工大学, 2020.
[25]	Yang J, Wu Y, Gao X, et al. Intraarterial versus intravenous tirofiban as an adjunct to endovascular thrombectomy for acute ischemic stroke[J]. Stroke, 2020, 51(10):2925-2933. doi: 10.1161/STROKEAHA.120.029994 URL
[26]	王文艳, 王松龄, 王丽萍. 镇肝熄风汤联合替罗非班治疗进展性脑梗死临床研究[J]. 新中医, 2020, 52(24):41-44.
[27]	Pan X, Zheng D, Zheng Y, et al. Safety and efficacy of tirofiban combined with endovascular treatment in acute ischaemic stroke[J]. Eur J Neurol, 2019, 26(8):1105-1110. doi: 10.1111/ene.13946 pmid: 30793464
[28]	杨直堂, 苏进营, 刘志军, 等. 替罗非班在脑梗死不同时期的安全性及对血小板活化的影响[J]. 中国实用神经疾病杂志, 2018, 21(20):2217-2221.
[29]	Zhang H, Zheng L. Statistical analysis for efficacy of tirofiban combined with ozagrel in the treatment of progressive cerebral infarction patients out of thrombolytic therapy time window[J]. Clinics, 2021, 76:e2728. doi: 10.6061/clinics/2021/e2728 URL
[30]	Cheng Z, Geng X, Gao J, et al. Intravenous administration of standard dose tirofiban after mechanical arterial recanalization is safe and relatively effective in acute ischemic stroke[J]. Aging and Disease, 2019, 10(5):1049-1057. doi: 10.14336/AD.2018.0922
[31]	Siebler M, Hennerici MG, Schneider D, et al. Safety of tirofiban in acute ischemic stroke: The SaTIS trial[J]. Stroke, 2011, 42(9):2388-2392. doi: 10.1161/STROKEAHA.110.599662 pmid: 21852609
[32]	李法良, 李琳, 王鑫. 超出溶栓时间窗急性缺血性脑卒中患者应用静脉注射替罗非班治疗的可行性[J]. 心理月刊, 2018, (3):216.
[33]	李坷, 张继中, 张钦昌. 国产替罗非班在急性进展性脑梗死治疗中的应用[J]. 中国实用神经疾病杂志, 2017, 20(1):117-118.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 33

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Liang Bingsong, Li Yuying, Zhang Qiping, Chen Yingdao, Li jian. Analysis of factors affecting clinical efficacy of Tirofiban in treating branch atheromatous disease [J]. Clinical Focus, 2023, 38(12): 1091-1094.
[2]	Yu Yifu, Yuan Chunhua. Research on the effects of diaphragm relaxation technique combined with resistance breathing training on motor ability of stroke survivors [J]. Clinical Focus, 2023, 38(11): 1002-1007.
[3]	. [J]. Clinical Focus, 2023, 38(11): 1034-1037.
[4]	Xu Wendeng, Shen Yi, Zhang Xiaofeng. Correlation between nonspecific ST-T abnormalities in electrocardiogram and recurrence of acute ischemic stroke [J]. Clinical Focus, 2023, 38(10): 883-886.
[5]	Li Zhiyong, Li Xing. Clinical value of multimodal ultrasound in screening middle cerebral artery stenosis in hypertensive patients [J]. Clinical Focus, 2023, 38(7): 613-617.
[6]	Xin Yanhong, Lang Guiyan, Chen Ziwei, Wang Dongyu. Value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in predicting cognitive impairment in patients with acute mild ischemic stroke [J]. Clinical Focus, 2023, 38(6): 504-509.
[7]	Xin Zaie. Subarachnoid hemorrhage misdiagnosed as menigitis: A case report and literature review [J]. Clinical Focus, 2023, 38(5): 448-450.
[8]	He Xiangyu, Pan Yan, Zhang Xiaolin. Correlation between serum lipoprotein-associated phospholipase A2 level and the severity and prognosis of acute ischemic stroke [J]. Clinical Focus, 2023, 38(4): 315-318.
[9]	Jia Yangjuan, Han Ning, Guo Hui, Li Yanpeng, Li Cancan, Li Jianguo. Value of Mini Mental State Examination and Montreal Cognitive Assessment in screening mild vascular cognitive impairment at post-stroke [J]. Clinical Focus, 2023, 38(3): 221-226.
[10]	Yao Meifen, Ding Gangyu, Xu Jianhua, Wang Guojiang. Efficacy and safety of recombinant tissue plasminogen activator in patients with acute mild ischemic stroke [J]. Clinical Focus, 2023, 38(3): 227-231.
[11]	. [J]. Clinical Focus, 2023, 38(1): 84-87.
[12]	. [J]. Clinical Focus, 2022, 37(12): 1142-1147.
[13]	Tang Qiuyan, Wei Xiaofeng, Feng Qian, Yang Huizhong, Yang Xuhong. Comparative analysis of Chinese guidelines for the endovascular treatment of acute ischemic stroke [J]. Clinical Focus, 2022, 37(11): 1037-1043.
[14]	Shu Ming, Yu Gui. Correlations between serum inflammatory factors, coagulation function and prognosis of neurological function in patients with acute cerebral infarction [J]. Clinical Focus, 2022, 37(10): 912-915.
[15]	Wang Huixin, Zhao Fangqing, Zhang Xinyan, Hou Xiaowen. Relationship between uric acid and prognosis of Chinese patients with acute ischemic stroke: A meta analysis [J]. Clinical Focus, 2022, 37(9): 785-790.